Loading…
Loading…
Jefferies has upgraded Reckitt Benckiser Group PLC (LSE:RKT, FRA:3RB, XETRA:3RB)to 'buy' from 'hold', raising its price target to 5,900p from 5,600p ahead of half-year results next week. The broker argues the market has overly discounted a run of setbacks that hit the consumer goods group in early 2026, most of which it classes as one-off and unlikely to recur beyond this year.
A jury in St. Louis on Thursday rejected claims that Reckitt unit Mead Johnson's specialized formula for preterm babies was to blame for causing an infant's dangerous bowel disease.
Reckitt Benckiser Group LON: RKT executives used an investor “Focus On” event to outline how the company is applying digital science, artificial intelligence and predictive modeling across its innovation process, saying the capabilities are intended to support faster product development, stronger launch execution and efficiency gains.
UBS sees nearly 60% total return potential in Reckitt Benckiser Group PLC (LSE:RKT, FRA:3RB, XETRA:3RB with the Swiss bank repeating a Buy rating and 7,400p price target. It comes after a meeting with the consumer goods group's finance chief reinforced confidence in 2026 targets, even as the broker acknowledged the Dettol and Durex owner has become a “show me story”.
Reckitt stock fell about 5% in early trading on Wednesday after the consumer goods group said first-quarter core like-for-like net revenue rose only 1.3%. The figure was well below the 2.9% analysts had expected, and warned that first-half adjusted operating margin would be roughly 200 basis points lower than a year earlier.
Lysol maker Reckitt Benckiser booked a rise in first-quarter like for like revenue, helped by strong emerging markets performance, where like-for-like sales grew 7.6%.
Reckitt Benckiser Group plc (RBGLY) Presents at UBS Global Consumer and Retail Conference Transcript
UBS maintained its 'buy' rating on Reckitt Benckiser Group PLC (LSE:RKT, FRA:3RB, XETRA:3RB), the consumer goods company behind brands including Dettol, Nurofen and Durex, on Friday but cut its price target by 5% to £74, arguing the market has yet to reward the group for an improved long-term earnings growth model. The note followed Thursday's results, in which Reckitt reported like-for-like (LFL) sales growth of 5.2% in the fourth quarter of 2025, a metric that strips out currency and portfolio changes, which UBS described as best in class among European peers.
No recent filings indexed.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for RBGPF and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.